Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹264.20down ₹3.85 (1.44%)BSE ₹264.80
Share price at the NSE close on 29 Oct 2026. Previous close ₹268.05.
29 Oct: open ₹269.90, high ₹269.90, low ₹261.80
52-week range of traded prices to 29 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,465 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,90,10349.4% delivered
Suven Life Sciences disputes and clarifications
19 filed, newest first.
May 2026
19 May · Legal
The exchange asked on 18 May 2026
Apr 2026
8 Apr · Legal
The exchange asked on 7 Apr 2026
Feb 2026
6 Feb · Legal
The exchange asked on 5 Feb 2026
Mar 2025
26 Mar · Legal
21 Mar · Legal
Feb 2025
26 Feb · Legal
Jan 2024
14 Jan · Legal
The exchange asked on 12 Jan 2024
3 Jan · Legal
The exchange asked on 2 Jan 2024
Apr 2022
1 Apr · Legal
The exchange asked on 31 Mar 2022
Oct 2021
11 Oct · Legal
The exchange asked on 8 Oct 2021
Dec 2020
28 Dec · Legal
The exchange asked on 24 Dec 2020
16 Dec · Legal
The exchange asked on 15 Dec 2020
Jun 2020
26 Jun · Legal
The exchange asked on 25 Jun 2020
Feb 2020
4 Feb · Legal
The exchange asked on 4 Feb 2020
Dec 2019
3 Dec · Legal
The exchange asked on 2 Dec 2019
Aug 2018
23 Aug · Legal
The exchange asked on 21 Aug 2018
May 2018
18 May · Legal
Exchange has sought clarification from Suven Life Sciences Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2015
3 Feb · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Suven Life Sciences Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Suven Life Sciences Limited has vide its letter inter-alia stated, "There is no information pending with us as on date having a bearing on the price/volume behavior in the scrip."